Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis.
Kim G, Chu R, Yousuf F, Tauhid S, Stazzone L, Houtchens MK, Stankiewicz JM, Severson C, Kimbrough D, Quintana FJ, Chitnis T, Weiner HL, Healy BC, Bakshi R. Kim G, et al. Among authors: severson c. Int J Neurosci. 2017 Nov;127(11):971-980. doi: 10.1080/00207454.2017.1283313. Epub 2017 Feb 2. Int J Neurosci. 2017. PMID: 28100092
IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production.
Maier LM, Lowe CE, Cooper J, Downes K, Anderson DE, Severson C, Clark PM, Healy B, Walker N, Aubin C, Oksenberg JR, Hauser SL, Compston A, Sawcer S; International Multiple Sclerosis Genetics Consortium; De Jager PL, Wicker LS, Todd JA, Hafler DA. Maier LM, et al. Among authors: severson c. PLoS Genet. 2009 Jan;5(1):e1000322. doi: 10.1371/journal.pgen.1000322. Epub 2009 Jan 2. PLoS Genet. 2009. PMID: 19119414 Free PMC article.
An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2.
Bakshi R, Neema M, Tauhid S, Healy BC, Glanz BI, Kim G, Miller J, Berkowitz JL, Bove R, Houtchens MK, Severson C, Stankiewicz JM, Stazzone L, Chitnis T, Guttmann CR, Weiner HL, Ceccarelli A. Bakshi R, et al. Among authors: severson c. Neuroreport. 2014 Oct 1;25(14):1156-61. doi: 10.1097/WNR.0000000000000244. Neuroreport. 2014. PMID: 25100554 Free PMC article.
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.
Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, Ashokkumar A, Bermel R, Ecklund D, Koepp M, Long J, Natarajan S, Ramachandran S, Skaramagas T, Thornell B, Yankey J, Agius M, Bashir K, Cohen B, Coyle P, Delgado S, Dewitt D, Flores A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch S, Miravalle A, Moses H, Ontaneda D, Perumal J, Racke M, Repovic P, Riley C, Severson C, Shinnar S, Suski V, Weinstock-Gutman B, Yadav V, Zabeti A. Fox RJ, et al. Among authors: severson c. Contemp Clin Trials. 2016 Sep;50:166-77. doi: 10.1016/j.cct.2016.08.009. Epub 2016 Aug 10. Contemp Clin Trials. 2016. PMID: 27521810 Free PMC article. Clinical Trial.
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators. Fox RJ, et al. Among authors: severson c. N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583. N Engl J Med. 2018. PMID: 30157388 Free PMC article. Clinical Trial.
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
Holroyd KB, Healy BC, Conway S, Houtchens M, Bakshi R, Bhattacharyya S, Bose G, Galetta K, Kaplan T, Severson C, Singhal T, Stazzone L, Zurawski J, Polgar-Turcsanyi M, Saxena S, Paul A, Glanz BI, Weiner HL, Chitnis T. Holroyd KB, et al. Among authors: severson c. Mult Scler Relat Disord. 2022 Nov;67:104079. doi: 10.1016/j.msard.2022.104079. Epub 2022 Jul 28. Mult Scler Relat Disord. 2022. PMID: 35952457 Free PMC article.
Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine.
Conway S, Saxena S, Baecher-Allan C, Krishnan R, Houtchens M, Glanz B, Saraceno TJ, Polgar-Turcsanyi M, Bose G, Bakshi R, Bhattacharyya S, Galetta K, Kaplan T, Severson C, Singhal T, Stazzone L, Zurawski J, Paul A, Weiner HL, Healy BC, Chitnis T. Conway S, et al. Among authors: severson c. Mult Scler J Exp Transl Clin. 2023 Apr 5;9(2):20552173231165196. doi: 10.1177/20552173231165196. eCollection 2023 Apr-Jun. Mult Scler J Exp Transl Clin. 2023. PMID: 37057191 Free PMC article.
64 results